



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/641,808	08/17/2000	Marlene Belfort	454311-2201.1	6356
20999	7590 02/21/20	3		
11101111111	R LAWRENCE & I	EXAMINER		
	VENUE- 10TH FL. ., NY 10151		NAVARRO, AI	BERT MARK
			ART UNIT	PAPER NUMBER
			1645	7
			DATE MAILED: 02/21/2003	3

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/641,808

Examiner

Applicant(s)

Mark Navarro

Art Unit 1645

Belfort et al

	The MAILING DATE of this communication appears	
Period fo	• •	
	RTENED STATUTORY PERIOD FOR REPLY IS SET AILING DATE OF THIS COMMUNICATION.	TO EXPIRE1 MONTH(S) FROM
	ns of time may be available under the provisions of 37 CFR 1.136 (a). In relate of this communication.	no event, however, may a reply be timely filed after SIX (6) MONTHS from the
	riod for reply specified above is less than thirty (30) days, a reply within th riod for reply is specified above, the maximum statutory period will apply a	e statutory minimum of thirty (30) days will be considered timely., and will expire SIX (6) MONTHS from the mailing date of this communication.
- Any reph	o reply within the set or extended period for reply will, by statute, cause the y received by the Office later than three months after the mailing date of the latent term adjustment. See 37 CFR 1.704(b).	
Status	atom torm adjustment. Good of Griff 1.704(b).	•
1) 🗆 F	Responsive to communication(s) filed on	
2a) 🗌 1	This action is FINAL . 2b) ☑ This acti	ion is non-final.
	Since this application is in condition for allowance e closed in accordance with the practice under <i>Ex pai</i>	except for formal matters, prosecution as to the merits is re Quayle, 1935 C.D. 11; 453 O.G. 213.
Dispositio	on of Claims	
4) 💢 (Claim(s) <u>1-72</u>	is/are pending in the application.
4a	ı) Of the above, claim(s)	is/are withdrawn from consideration.
5) 🗆 C	Claim(s)	is/are allowed.
6) 🗆 (Claim(s)	is/are rejected.
7) 🗌 (Claim(s)	is/are objected to.
8) 💢 (Claims <u>1-72</u>	are subject to restriction and/or election requirement.
Applicati	on Papers	
9) 🗌 1	The specification is objected to by the Examiner.	
10) 🗆 🗆	The drawing(s) filed on is/are	a) \square accepted or b) \square objected to by the Examiner.
	Applicant may not request that any objection to the de	rawing(s) be held in abeyance. See 37 CFR 1.85(a).
11) 🗌 📑	The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.
_	If approved, corrected drawings are required in reply t	o this Office action.
12) 🗌 🗵	The oath or declaration is objected to by the Exami	ner.
	inder 35 U.S.C. §§ 119 and 120	
_	Acknowledgement is made of a claim for foreign pr	fority under 35 U.S.C. § 119(a)-(d) or (f).
	All b)☐ Some* c)☐ None of:	
	. Certified copies of the priority documents have	
	. Caring of the provided country documents have	
	application from the International Burea the attached detailed Office action for a list of the	
14) 🗌 🔏	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).
a) 🗀	The translation of the foreign language provisional	l application has been received.
15) 🗌 🔏	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.
Attachmen		
	ce of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).
	ce of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)
3) Unfor	mation Disclosure Statement(s) (PTO-1449) Paper No(s)	6) Other:

Application/Control Number: 09/641,808 Page 2

Art Unit: 1645

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-33, drawn to inteins, classified in class 530, subclass 350.
 - II. Claims 34-38 and 67-72, drawn to DNA, classified in class 536, subclass 23.1.
 - III. Claims 39-47, drawn to methods of producing a protein enzymatically, classified in class 435, subclass 68.1.
 - IV. Claims 48-49, drawn to methods of purification, classified in class 435, subclass 7.1.
 - V. Claims 50-52, drawn to methods of preparing an intein comprising random mutagenesis, classified in class 435, subclass 69.1.
 - VI. Claims 53-60, drawn to methods of screening for intein cleavage activity, classified in class 435, subclass 7.4.
 - VII. Claims 61-66, drawn to methods of determining amino acid residues in an intein that play a role in cleavage activity, classified in class 435, subclass 4.
- 2. The inventions are distinct, each from the other because of the following reasons:

Invention I drawn to a polypeptide and Invention II drawn to a polynucleotide are distinct since they are products with different structure and biological properties. The polypeptide is made of amino acids whereas the claimed nucleic acid is made of nucleotides. Further methods

Application/Control Number: 09/641,808 Page 3

Art Unit: 1645

known in the art used to make the polypeptide require different reagents and parameters from the methods of making DNA encoding the protein and the method of making the polypeptide does not require the DNA. For instance, the protein can be made by Merrifield chemical synthesis or affinity chromatography.

Invention III, drawn to methods of producing a protein enzymatically, is distinct from Groups I-II and IV-VII, since it requires additional biological reagents and parameters for producing the protein.

Invention IV, drawn to methods of purifying a protein, is distinct from Groups I-III and V-VII, since it requires additional biological reagents and parameters for purifying the protein.

Invention V, drawn to methods of preparing an intein comprising random mutagenesis, is distinct from Groups I-IV and VI-VII, since it requires additional biological reagents and parameters for inserting nucleotide substitutions.

Invention VI, drawn to methods of screening for intein cleavage activity, is distinct from Groups I-V and VII, since it requires additional biological reagents and parameters detecting intein cleavage activity.

Invention VII, drawn to methods of determining amino acid residues in an intein that play a role in cleavage activity, is distinct from Groups I-VII, since it requires additional biological reagents and parameters for detecting amino acids which are responsible for biological activity.

Application/Control Number: 09/641,808

Page 4

Art Unit: 1645

Because these inventions are distinct for the reasons given above and have acquired a

separate status in the art because of their separate classification and their recognized divergent

subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37 CFR

1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

named inventors is no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the

fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Mark Navarro whose telephone number is (703) 306-3225.

Mark Navarro

Primary Examiner

February 13, 2003